CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $4.08B, above the global median of $1.14B
- PositionDebt-to-equity is 3.91×, higher than 95% of its Medical Devices peers (median 0.16×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.08BUSDvs all stocks (USD)
Revenue (TTM)
825.34MUSDvs all stocks (USD)
Profit Margin
-1.69%vs Medical Devices peers
Beta
1.46xvs all stocks
52-Week Change
-32.18%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
4.08BUSDvs all stocks (USD)
Enterprise Value
4.13BUSDvs all stocks (USD)
Forward P/E
97.36xvs Medical Devices peers
Price to Sales (TTM)
4.84xvs Medical Devices peers
Price to Book (MRQ)
21.48xvs Medical Devices peers
Enterprise to Revenue
5.01xvs Medical Devices peers
Gross Margin
72.80%vs Medical Devices peers
Profit Margin
-1.69%vs Medical Devices peers
Operating Margin
7.94%vs Medical Devices peers
Return on Assets (TTM)
0.65%vs Medical Devices peers
Return on Equity (TTM)
-9.63%vs Medical Devices peers
Revenue (TTM)
825.34MUSDvs all stocks (USD)
Revenue per Share (TTM)
25.43USDUpdated Oct 27, 2026Quarterly Revenue Growth
20.10%vs Medical Devices peers
Gross Profit (TTM)
589.73MUSDvs all stocks (USD)
EBITDA (TTM)
493.00KUSDvs all stocks (USD)
Net Income (TTM)
-13.95MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
20.08%vs Medical Devices peers
Operating Cash Flow (TTM)
86.00MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
81.83MUSDvs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Oct 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
747.14MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
219.89MUSDFY2025 · Dec 31, 2025Gross Profit
527.25MUSDFY2025 · Dec 31, 2025Operating Income
-52.95MUSDvs all stocks (USD)
Pre-tax Income
-43.60MUSDFY2025 · Dec 31, 2025Income Tax Expense
953.00KUSDFY2025 · Dec 31, 2025Net Income
-44.55MUSDFY2025 · Dec 31, 2025EBIT
-30.44MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
493.00KUSDFY2025 · Dec 31, 2025Research & Development
87.65MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
492.55MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
21.52MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
13.15MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.39USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.39USDFY2025 · Dec 31, 2025Basic Shares Outstanding
32.00MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
32.00MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-44.55MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-37.09MUSDFY2025 · Dec 31, 2025Free Cash Flow
-83.43MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
244.37MUSDFY2025 · Dec 31, 2025Income Tax Paid
869.00KUSDFY2025 · Dec 31, 2025Interest Paid
3.77MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-44.55MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
26.48MUSDFY2025 · Dec 31, 2025Stock-based Compensation
88.28MUSDFY2025 · Dec 31, 2025Other Non-cash Items
7.06MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-95.43MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-18.93MUSDFY2025 · Dec 31, 2025Capital Expenditures
-46.34MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-468.41MUSDFY2025 · Dec 31, 2025Sale of Investments
237.70MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-277.06MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
32.94MSharesUpdated Oct 27, 2026Float Shares
30.29MSharesUpdated Oct 27, 2026Shares Short
3.03MSharesUpdated Oct 27, 2026Short Ratio
5.63daysvs all stocks
Short % of Shares Outstanding
9.29%vs all stocks
% Held by Insiders
1.17%vs all stocks
% Held by Institutions
107.83%vs all stocks
Total Cash (MRQ)
591.27MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
17.94USDUpdated Oct 27, 2026Total Debt (MRQ)
727.35MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
3.91xvs Medical Devices peers
Current Ratio (MRQ)
3.85xvs Medical Devices peers
Book Value per Share (MRQ)
5.64USDUpdated Oct 27, 2026Total Assets
1.02BUSDvs all stocks (USD)
Total Current Assets
702.76MUSDFY2025 · Dec 31, 2025Total Liabilities
867.30MUSDFY2025 · Dec 31, 2025Total Non-current Assets
317.28MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
715.41MUSDFY2025 · Dec 31, 2025Total Current Liabilities
151.89MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
236.01MUSDFY2025 · Dec 31, 2025Other Short-term Investments
347.75MUSDFY2025 · Dec 31, 2025Accounts Receivable
75.71MUSDFY2025 · Dec 31, 2025Inventory
21.63MUSDFY2025 · Dec 31, 2025Accounts Payable
2.26MUSDFY2025 · Dec 31, 2025Short-term Debt
16.69MUSDFY2025 · Dec 31, 2025Deferred Revenue
4.20MUSDFY2025 · Dec 31, 2025Long-term Debt
714.50MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
908.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
32.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-803.45MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
152.75MUSDvs all stocks (USD)
Treasury Stock
25.00MUSDFY2025 · Dec 31, 202552-Week Low
100.70USDUpdated Oct 27, 202652-Week High
212.00USDUpdated Oct 27, 202652-Week Change
-32.18%vs all stocks
Beta
1.46xvs all stocks
50-Day MA
114.85USDUpdated Oct 27, 2026200-Day MA
123.56USDUpdated Oct 27, 2026Avg 10-Day Volume
466.69KSharesUpdated Oct 27, 2026Avg 30-Day Volume
497.47KSharesUpdated Oct 27, 2026Diluted EPS (TTM)
-0.4200USDUpdated Oct 27, 2026Other Income / Expense
984.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 3.91×, higher than 95% of its Medical Devices peers (median 0.16×)Significant
Debt-to-equity: 3.91Industry median: 0.16Industry P95: 1.99Peers compared: 62.00
Price-to-book is 21.48×, higher than 95% of its Medical Devices peers (median 3.21×)Significant
Price-to-book: 21.48Industry median: 3.21Industry P95: 13.23Peers compared: 62.00
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.73Profit Margin: -0.02
Significant cash reserves alongside high leverageNotable
Cash (USD): 591,273,984Total Debt (USD): 727,348,992Debt-to-Equity: 3.91
Financial Health
Altman Z-Score 3: safe zoneNotable
Altman Z-Score: 3.00
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $4.08B, above the global median of $1.14BNotable
Market cap (USD): 4,083,786,441Global Median: 1,138,450,684.034
Revenue is $825.34M, above the global median of $562.3MNotable
Revenue (USD): 825,336,000Global Median: 562,304,852.367
Levered free cash flow is $81.83M, above the global median of $18.69MNotable
Levered free cash flow (USD): 81,834,128Global Median: 18,689,872.41
Companies that share the same coordination system — how they create, deliver, or capture value.
Indivior Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Apeloa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Liquidia Corporation
Tier 1ProductionApproval-Gated PipelineRule
J.B. Chemicals & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Relay Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
China Medical System Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
GenScript Biotech Corporation
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
Xuanzhu Biopharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
T-Mobile US, Inc.
1 interpretationElevated Leverage on Three Denominators
Travere Therapeutics Inc.
1 interpretationElevated Leverage on Three Denominators
Gannett Co., Inc.
1 interpretationElevated Leverage on Three Denominators